Literature DB >> 6801127

Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies.

A U Krettli, Z Brener.   

Abstract

A dissociation between antibodies involved in the diagnosis of Trypanosoma cruzi infections and those participating in resistance against this parasite is reported. Mice immunized with different T. cruzi antigens (frozen-thawed culture forms, glutaraldehyde-fixed blood trypomastigotes, "metabolic antigens" from blood parasites, and surface glycoprotein from epimastigotes) present only antibodies detected by conventional immunofluorescence tests (IFA) using fixed parasites. However, mice chronically infected with T. cruzi harbor both reactive IFA antibodies and antibodies against living blood forms (ALBA) detectable by complement-mediated lysis (CML). Challenge of the various groups of animals with virulent T. cruzi show that only mice presenting ALBA are strongly resistant. In addition, the antibody lytic activity is lost in mice parasitologically cured after specific treatment. Those findings strongly suggest that ALBA are good markers for monitoring protection in experiments of vaccination against T. cruzi. They also support our previous suggestion that the search for antibodies against living blood forms, detected mainly by CML, is an important element in establishing a reliable criterion of cure in human Chagas' disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6801127

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  Use of the Trypanosoma cruzi recombinant complement regulatory protein to evaluate therapeutic efficacy following treatment of chronic chagasic patients.

Authors:  Wendell S F Meira; Lúcia M C Galvão; Eliane D Gontijo; George L L Machado-Coelho; Karen A Norris; Egler Chiari
Journal:  J Clin Microbiol       Date:  2004-02       Impact factor: 5.948

2.  Why does GM1 induce a potent beneficial response to experimental Chagas disease?

Authors:  S Cossy Isasi; C A Condat; G J Sibona
Journal:  HFSP J       Date:  2009-01-21

3.  Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection.

Authors:  B Wizel; N Garg; R L Tarleton
Journal:  Infect Immun       Date:  1998-11       Impact factor: 3.441

4.  Trypanosoma cruzi infection in rats induced early lesion of the heart noradrenergic nerve terminals by a complement-independent mechanism.

Authors:  C R Machado; D A de Oliveira; M J Magalhaes; E M Carvalho; F J Ramalho-Pinto
Journal:  J Neural Transm Gen Sect       Date:  1994

5.  Isotype of lytic antibodies in serum of Chagas' disease patients.

Authors:  S A Romeiro; H A Takehara; I Mota
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

6.  Purification of a Trypanosoma cruzi membrane glycoprotein which elicits lytic antibodies.

Authors:  K A Norris; G Harth; M So
Journal:  Infect Immun       Date:  1989-08       Impact factor: 3.441

7.  Double-blind study to evaluate flow cytometry analysis of anti-live trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease.

Authors:  Olindo Assis Martins-Filho; Silvana Maria Eloi-Santos; Andréa Teixeira Carvalho; Rodrigo Corrêa Oliveira; Anis Rassi; Alejandro Ostemayer Luquetti; Gustavo Gabriel Rassi; Zigman Brener
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

Review 8.  Current understanding of immunity to Trypanosoma cruzi infection and pathogenesis of Chagas disease.

Authors:  Fabiana S Machado; Walderez O Dutra; Lisia Esper; Kenneth J Gollob; Mauro M Teixeira; Stephen M Factor; Louis M Weiss; Fnu Nagajyothi; Herbert B Tanowitz; Nisha J Garg
Journal:  Semin Immunopathol       Date:  2012-10-18       Impact factor: 9.623

9.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

10.  Immunization with Trypanosoma cruzi epimastigote antigens incorporated into iscoms protects against lethal challenge in mice.

Authors:  F G Araujo; B Morein
Journal:  Infect Immun       Date:  1991-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.